Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223


Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.

Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd.

Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20.


Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.

Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, Lyss AP, Horn L, Stinchcombe TE, Schiller JH.

J Clin Oncol. 2019 Sep 10;37(26):2360-2367. doi: 10.1200/JCO.19.01006. Epub 2019 Jul 30.


Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.

Wang T, Lu R, Lai S, Schiller JH, Zhou FL, Ci B, Wang S, Gao X, Yao B, Gerber DE, Johnson DH, Xiao G, Xie Y.

Cancer Inform. 2019 Apr 5;18:1176935119837547. doi: 10.1177/1176935119837547. eCollection 2019.


A New Standard of Care for Advanced Lung Cancer.

Schiller JH.

N Engl J Med. 2018 May 31;378(22):2135-2137. doi: 10.1056/NEJMe1804364. No abstract available.


Generalizability of Competency Assessment Scores Across and Within Clerkships: How Students, Assessors, and Clerkships Matter.

Zaidi NLB, Kreiter CD, Castaneda PR, Schiller JH, Yang J, Grum CM, Hammoud MM, Gruppen LD, Santen SA.

Acad Med. 2018 Aug;93(8):1212-1217. doi: 10.1097/ACM.0000000000002262.


Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ.

Lung Cancer. 2018 Mar;117:44-49. doi: 10.1016/j.lungcan.2018.01.010. Epub 2018 Feb 3.


Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN.

Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.


Characteristics of multi-institutional health sciences education research: a systematic review.

Schiller JH, Beck Dallaghan GL, Kind T, McLauchlan H, Gigante J, Smith S.

J Med Libr Assoc. 2017 Oct;105(4):328-335. doi: 10.5195/jmla.2017.134. Epub 2017 Oct 1. Review.


Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Smith TJ, Hanna N, Johnson D, Baker S Jr, Biermann WA, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Tashbar J, Temin S, Masters G.

J Oncol Pract. 2017 Dec;13(12):780-783. doi: 10.1200/JOP.2017.027367. Epub 2017 Oct 5. No abstract available.


Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).

Argiris A, Lee JW, Stevenson J, Sulecki MG, Hugec V, Choong NW, Saltzman JN, Song W, Hansen RM, Evans TL, Ramalingam SS, Schiller JH.

Ann Oncol. 2017 Dec 1;28(12):3037-3043. doi: 10.1093/annonc/mdx534.


Responsible Milestone-Based Educational Handover With Individualized Learning Plan From Undergraduate to Graduate Pediatric Medical Education.

Schiller JH, Burrows HL, Fleming AE, Keeley MG, Wozniak L, Santen SA.

Acad Pediatr. 2018 Mar;18(2):231-233. doi: 10.1016/j.acap.2017.09.010. Epub 2017 Sep 20.


Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G.

J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14. Erratum in: J Clin Oncol. 2018 Jan 20;36(3):304.


Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE.

J Thorac Oncol. 2017 Oct;12(10):1489-1495. doi: 10.1016/j.jtho.2017.07.020. Epub 2017 Aug 9.


Medical Students' Use of Different Coping Strategies and Relationship With Academic Performance in Preclinical and Clinical Years.

Schiller JH, Stansfield RB, Belmonte DC, Purkiss JA, Reddy RM, House JB, Santen SA.

Teach Learn Med. 2018 Jan-Mar;30(1):15-21. doi: 10.1080/10401334.2017.1347046. Epub 2017 Jul 28.


Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X.

J Clin Oncol. 2017 Sep 1;35(25):2885-2892. doi: 10.1200/JCO.2016.71.4758. Epub 2017 May 11.


Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).

Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE; Alliance for Clinical Trials in Oncology.

J Clin Oncol. 2017 Jul 1;35(19):2184-2192. doi: 10.1200/JCO.2016.71.3743. Epub 2017 May 10.


Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems.

Gerber DE, Reimer T, Williams EL, Gill M, Loudat Priddy L, Bergestuen D, Schiller JH, Kirkpatrick H, Craddock Lee SJ.

J Oncol Pract. 2016 Nov;12(11):1020-1028. Epub 2016 Sep 30.


Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD.

Oncotarget. 2016 May 31;7(22):31639-51. doi: 10.18632/oncotarget.9335.


Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH.

Cancer. 2016 Aug 1;122(15):2371-8. doi: 10.1002/cncr.30062. Epub 2016 May 10.


Attitudes and Stereotypes in Lung Cancer versus Breast Cancer.

Sriram N, Mills J, Lang E, Dickson HK, Hamann HA, Nosek BA, Schiller JH.

PLoS One. 2015 Dec 23;10(12):e0145715. doi: 10.1371/journal.pone.0145715. eCollection 2015.


Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH.

Lung Cancer. 2015 Dec;90(3):534-41. doi: 10.1016/j.lungcan.2015.10.008. Epub 2015 Oct 9.


The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases.

Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R.

Clin Cancer Res. 2015 Oct 15;21(20):4561-8. doi: 10.1158/1078-0432.CCR-14-3246.


Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH; American Society of Clinical Oncology Clinical Practice.

J Clin Oncol. 2015 Oct 20;33(30):3488-515. doi: 10.1200/JCO.2015.62.1342. Epub 2015 Aug 31. Erratum in: J Clin Oncol. 2016 Apr 10;34(11):1287.


Correction to Lancet Oncol 2015; 16: 738. Anti-EGFR monoclonal antibodies in lung cancer treatment.

Schiller JH.

Lancet Oncol. 2015 Jul;16(7):e313. doi: 10.1016/S1470-2045(15)00071-6. No abstract available.


Anti-EGFR monoclonal antibodies in lung cancer treatment.

Schiller JH.

Lancet Oncol. 2015 Jul;16(7):738-9. doi: 10.1016/S1470-2045(15)00020-0. Epub 2015 Jun 1. No abstract available. Erratum in: Lancet Oncol. 2015 Jul;16(7):e313.


Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.

Langer CJ, Socinski MA, Patel JD, Sandler AB, Schiller JH, Leon L, Hazard SJ, Ramalingam SS.

Am J Clin Oncol. 2016 Oct;39(5):441-7. doi: 10.1097/COC.0000000000000163.


A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH.

Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2.


Reply to A. Braillon.

Johnson DH, Schiller JH, Bunn PA.

J Clin Oncol. 2014 Nov 1;32(31):3575. doi: 10.1200/JCO.2014.57.2545. Epub 2014 Sep 15. No abstract available.


Medical school handoff education improves postgraduate trainee performance and confidence.

Stojan JN, Schiller JH, Mullan P, Fitzgerald JT, Christner J, Ross PT, Middlemas S, Haftel H, Stansfield RB, Lypson ML.

Med Teach. 2015 Mar;37(3):281-8. doi: 10.3109/0142159X.2014.947939. Epub 2014 Aug 26.


Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).

Pillai RN, Aisner J, Dahlberg SE, Rogers JS, DiPaola RS, Aisner S, Ramalingam SS, Schiller JH.

Cancer Chemother Pharmacol. 2014 Jul;74(1):177-83. doi: 10.1007/s00280-014-2427-7. Epub 2014 May 24.


Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.

Gazdar A, Robinson L, Oliver D, Xing C, Travis WD, Soh J, Toyooka S, Watumull L, Xie Y, Kernstine K, Schiller JH.

J Thorac Oncol. 2014 Apr;9(4):456-63. doi: 10.1097/JTO.0000000000000130.


Recent clinical advances in lung cancer management.

Johnson DH, Schiller JH, Bunn PA Jr.

J Clin Oncol. 2014 Apr 1;32(10):973-82. doi: 10.1200/JCO.2013.53.1228. Epub 2014 Feb 24. Review. Erratum in: J Clin Oncol. 2014 May 10;32(14):1520. Dosage error in article text.


Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.


E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.

Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, Gounder M, Rausch PG, Axelrod RS, Schiller JH.

Cancer Chemother Pharmacol. 2014 Jan;73(1):171-80. doi: 10.1007/s00280-013-2338-z. Epub 2013 Nov 28.


Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH.

Eur J Cancer. 2014 Jan;50(2):302-8. doi: 10.1016/j.ejca.2013.10.006. Epub 2013 Nov 15.


Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (SOAPP) study.

Hamann HA, Lee JW, Schiller JH, Horn L, Wagner LI, Chang VT, Fisch MJ.

J Thorac Oncol. 2013 Dec;8(12):1474-83. doi: 10.1097/01.JTO.0000437501.83763.5d.


Stigma among patients with lung cancer: a patient-reported measurement model.

Hamann HA, Ostroff JS, Marks EG, Gerber DE, Schiller JH, Lee SJ.

Psychooncology. 2014 Jan;23(1):81-92. doi: 10.1002/pon.3371. Epub 2013 Oct 3.


Training may impact shift work mentality in students.

Stojan JN, Schiller JH, Fitzgerald JT, Lypson ML.

Med Educ. 2013 Nov;47(11):1126-7. doi: 10.1111/medu.12321. No abstract available.


Long-term gain after team-based learning experience in a pediatric clerkship.

Warrier KS, Schiller JH, Frei NR, Haftel HM, Christner JG.

Teach Learn Med. 2013;25(4):300-5. doi: 10.1080/10401334.2013.827975.


Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH.

Br J Cancer. 2013 Sep 17;109(6):1476-81. doi: 10.1038/bjc.2013.472. Epub 2013 Aug 13.


Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.

Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH.

J Thorac Oncol. 2013 Sep;8(9):1121-7. doi: 10.1097/JTO.0b013e31829cf942.


Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).

Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH.

J Thorac Oncol. 2013 Aug;8(8):1075-83. doi: 10.1097/JTO.0b013e3182937317.


Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.

Hoang T, Dahlberg SE, Schiller JH, Johnson DH.

Lung Cancer. 2013 Jul;81(1):47-52. doi: 10.1016/j.lungcan.2013.03.018. Epub 2013 Apr 21.


Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V.

Invest New Drugs. 2014 Feb;32(1):123-34. doi: 10.1007/s10637-013-9958-3. Epub 2013 Apr 12.


What parents want from emails with their pediatrician: implications for teaching communication skills.

Schiller JH, Christner JG, Stansfield RB, Watnick CS, Mullan PB.

Patient Educ Couns. 2013 Jul;92(1):61-6. doi: 10.1016/j.pec.2013.02.012. Epub 2013 Mar 17.


Non-small-cell lung cancer: then and now.

Schiller JH, Gandara DR, Goss GD, Vokes EE.

J Clin Oncol. 2013 Mar 10;31(8):981-3. doi: 10.1200/JCO.2012.47.5772. Epub 2013 Feb 11. No abstract available.


Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.

Gerber DE, Schiller JH.

J Clin Oncol. 2013 Mar 10;31(8):1009-20. doi: 10.1200/JCO.2012.43.7459. Epub 2013 Feb 11. Review.


An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial.

Gustafson DH, DuBenske LL, Namkoong K, Hawkins R, Chih MY, Atwood AK, Johnson R, Bhattacharya A, Carmack CL, Traynor AM, Campbell TC, Buss MK, Govindan R, Schiller JH, Cleary JF.

Cancer. 2013 May 1;119(9):1744-51. doi: 10.1002/cncr.27939. Epub 2013 Jan 25.

Supplemental Content

Loading ...
Support Center